Cargando…

Overcome Double Trouble: Baloxavir Marboxil Suppresses Influenza Thereby Mitigating Secondary Invasive Pulmonary Aspergillosis

Influenza-associated pulmonary aspergillosis (IAPA) is a global recognized superinfection in critically ill influenza patients. Baloxavir marboxil, a cap-dependent endonuclease inhibitor, is a newly approved anti-influenza therapeutic. Although the benefits as a treatment for influenza are clear, it...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seldeslachts, Laura, Jacobs, Cato, Tielemans, Birger, Vanhoffelen, Eliane, Van der Sloten, Lauren, Humblet-Baron, Stephanie, Naesens, Lieve, Lagrou, Katrien, Verbeken, Erik, Wauters, Joost, Vande Velde, Greetje
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777735/ https://www.ncbi.nlm.nih.gov/pubmed/35049941 http://dx.doi.org/10.3390/jof8010001

Ejemplares similares

Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model
por: Seldeslachts, Laura, et al.
Publicado: (2021)

A Pathology-based Case Series of Influenza- and COVID-19–associated Pulmonary Aspergillosis: The Proof Is in the Tissue
por: Vanderbeke, Lore, et al.
Publicado: (2023)

Efficacy of baloxavir marboxil on household transmission of influenza infection
por: Umemura, Takumi, et al.
Publicado: (2020)

Baloxavir Marboxil: An Original New Drug against Influenza
por: Dufrasne, François
Publicado: (2021)

Longitudinal multimodal imaging-compatible mouse model of triazole-sensitive and -resistant invasive pulmonary aspergillosis
por: Resendiz-Sharpe, Agustin, et al.
Publicado: (2022)

Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
por: Omoto, Shinya, et al.
Publicado: (2018)

Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil
por: Takashita, Emi, et al.
Publicado: (2018)

The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets
por: Kitano, Mitsutaka, et al.
Publicado: (2020)

Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes
por: Hirotsu, Nobuo, et al.
Publicado: (2020)

Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens
por: Twabela, Augustin, et al.
Publicado: (2020)

Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals
por: Liu, Yanmei, et al.
Publicado: (2022)

1350. Therapeutic Effects of Baloxavir Marboxil against Influenza A Virus Infection in Ferrets
por: Kitano, Mitsutaka, et al.
Publicado: (2018)

Powerful and Real-Time Quantification of Antifungal Efficacy against Triazole-Resistant and -Susceptible Aspergillus fumigatus Infections in Galleria mellonella by Longitudinal Bioluminescence Imaging
por: Vanhoffelen, Eliane, et al.
Publicado: (2023)

Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Influenza Patients at High Risk of Complications
por: Koshimichi, Hiroki, et al.
Publicado: (2020)

Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study
por: Yokoyama, Takato, et al.
Publicado: (2020)

Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil
por: Kiso, Maki, et al.
Publicado: (2019)

922. Cost-effectiveness of baloxavir marboxil versus oseltamivir or no treatment for the management of influenza in the United States
por: Hansen, Svenn, et al.
Publicado: (2023)

Clinical Efficacy of Baloxavir Marboxil in the Treatment of Seasonal Influenza in Adult Patients: A Prospective Observational Study
por: Yoshino, Yusuke, et al.
Publicado: (2020)

The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor
por: Todd, Brendan, et al.
Publicado: (2021)

Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects
por: Kim, Yun, et al.
Publicado: (2021)

Baloxavir marboxil: un potente inhibidor de la endonucleasa cap-dependiente de los virus gripales
por: Reina, Jordi, et al.
Publicado: (2019)

LB16. Phase 3 Trial of Baloxavir Marboxil in High-Risk Influenza Patients (CAPSTONE-2 Study)
por: Ison, Michael G, et al.
Publicado: (2018)

Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
por: Lou, Yan, et al.
Publicado: (2021)

1518. Real-World Comparative Effectiveness of Baloxavir Marboxil versus Oseltamivir on Influenza-Related Complication and Resource Utilization
por: Neuberger, Eddie, et al.
Publicado: (2020)

Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings
por: Koshimichi, Hiroki, et al.
Publicado: (2018)

Molecular Dynamics Simulation reveals the mechanism by which the Influenza Cap-dependent Endonuclease acquires resistance against Baloxavir marboxil
por: Yoshino, Ryunosuke, et al.
Publicado: (2019)

Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection
por: Taniguchi, Keiichi, et al.
Publicado: (2022)

Early Fever Resolution in Early Childhood Influenza Treated with Baloxavir Marboxil: A Retrospective Study Compared to Those with Oseltamivir
por: Nezu, Keiko, et al.
Publicado: (2023)

Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil
por: Nakauchi, Mina, et al.
Publicado: (2020)

Improved in vitro Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002
por: Hamza, Hazem, et al.
Publicado: (2021)

Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study
por: Komeda, Takuji, et al.
Publicado: (2020)

Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study
por: Feys, Simon, et al.
Publicado: (2022)

Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil
por: Taniguchi, Keiichi, et al.
Publicado: (2019)

Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza A virus detected in clinical trials of baloxavir marboxil
por: Hashimoto, Takashi, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection
por: Ando, Yoshinori, et al.
Publicado: (2020)

967. Inhibition of Host Neuraminidase Increases Susceptibility to Invasive Pulmonary Aspergillosis
por: Van De Veerdonk, Frank, et al.
Publicado: (2018)

Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection
por: Fukao, Keita, et al.
Publicado: (2019)

S3.3d Influenza versus COVID-19-associated pulmonary aspergillosis: Profiling lower respiratory tract epithelial and myeloid innate immunity in patient samples
por: Feys, Simon, et al.
Publicado: (2022)

Effective Anti-SARS-CoV-2 RNA Dependent RNA Polymerase Drugs Based on Docking Methods: The Case of Milbemycin, Ivermectin, and Baloxavir Marboxil
por: Daghir Janabi, Ali Hassan
Publicado: (2020)

Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5–11 Years of Age: A Post Hoc Analysis of a Phase 3 Study
por: Baker, Jeffery B., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iae7safg223f4gjk88j3r8eju5